Automate Your Wheel Strategy on PASG
With Tiblio's Option Bot, you can configure your own wheel strategy including PASG - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PASG
- Rev/Share 0.0
- Book/Share 0.752
- PB 0.6007
- Debt/Equity 0.5377
- CurrentRatio 3.7402
- ROIC -0.958
- MktCap 28072387.0
- FreeCF/Share -0.6908
- PFCF -0.6542
- PE -0.4421
- Debt/Assets 0.292
- DivYield 0
- ROE -0.9359
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PASG | Rodman & Renshaw | -- | Buy | -- | $7 | Sept. 3, 2024 |
News
Passage Bio to Participate in Upcoming Investor Conferences
PASG
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:
Read More
About Passage Bio, Inc. (PASG)
- IPO Date 2020-02-28
- Website https://www.passagebio.com
- Industry Biotechnology
- CEO Dr. William Chou M.D.
- Employees 60
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.